Abstract. Erythropoietic agents, a cornerstone of management, are a major component of the cost of renal replacement therapy.
Anemia is a common feature of chronic kidney disease. The physiologic response to anemia includes vasodilation, increased venous return, cardiac enlargement, and increased cardiac output (1) . Observational studies in hemodialysis patients have found anemia to be associated with higher mortality in populations in which the vast majority of patients had hemoglobin levels between 6 and 12 g/dl (2) (3) (4) . Associations of anemia with hospitalization and resource utilization also have been reported (5, 6 ). An epidemiologic study that focused on patients with higher hemoglobin levels yielded similar results, finding an inverse association between hospitalization and hemoglobin level in patients whose hematocrit ranged from 36 to 39% (7) . Recently, the related concepts of anemia avoidance and full anemia correction have attracted considerable research interest. The benefits of such an approach, which may include lower cardiac mass, lower risks of cardiac failure, and better quality of life, remain unclear, as do the risks, such as hypertension, thrombosis, and expense (8 -10) .
Because of superior survival associations in observational studies and improved quality of life and partial regression of left ventricular hypertrophy in controlled trials, a hemoglobin target level of 11 to 12 g/dl was recommended in the National Kidney Foundation Dialysis Outcomes Quality Initiative (DOQI) clinical practice guidelines on anemia of chronic renal failure (11) . It has long been believed that peritoneal dialysis patients tend to be less anemic than hemodialysis patients (12) (13) (14) (15) (16) (17) (18) (19) . Possible biologic mechanisms for this include superior preservation of residual renal function in peritoneal dialysis patients, blood loss during dialysis sessions in hemodialysis patients, and differences between modalities in the cyclicity and pattern of uremic toxin removal (20) .
Erythropoietic agents, whose use is a cornerstone of renal anemia management, are a major component of the cost of renal replacement therapy. Few, if any, contemporary, longitudinal population studies have described the time interval between dialysis initiation and attainment of the DOQI hemoglobin target level in the United States. Similarly, few studies have compared hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis populations. This study attempted partly to address this information gap.
Materials and Methods

Objectives
The major objectives of this retrospective study were to compare (on a month-by-month basis) hemodialysis and peritoneal dialysis patients on the following grounds: (1) proportion receiving erythropoietin during the first year of dialysis therapy, (2) erythropoietin doses in the year after initiation of erythropoietin, and (3) hemoglobin levels in the year after initiation of erythropoietin. Objective 1 con-stituted the "erythropoietin utilization" component, and objectives 2 and 3 constituted the "erythropoietin dose/hemoglobin level" component of the study.
Patient Population
Patients were selected for study when they (1) began dialysis between 1995 and 2000, (2) had Medicare as their primary payer, (3) were 65 yr old or older at initiation of dialysis therapy, (4) had no erythropoietin claims before initiation of dialysis therapy, and (5) did not have a switch in dialysis modality in the first 6 mo of dialysis therapy (study entry period).
Medicare data were used because Medicare health insurance is routinely available in the United States to any member of the general population who is 65 yr old or older and to anyone with ESRD treated with dialysis or renal transplantation (21) . The years 1995 to 2000 were chosen because they were relatively contemporary at the time the study was performed, because 1995 was the first year of use of the current Centers for Medicare & Medicaid Services Medical Evidence Report (CMS-2728) at dialysis inception, and because 2000 was the most recent complete year of Medicare claims data. The study was limited to patients who were 65 yr old or older and had Medicare as their primary payer to minimize the possibility of missing erythropoietin claims, which were used in this study to calculate erythropoietin doses and associated hemoglobin values. The 6-mo study entry period was used to create a group of patients who exhibited clinical stability with regard to dialysis modality.
Statistical Analyses
The proportion of patients who received erythropoietin, the total erythropoietin dose, and the average monthly hemoglobin level were calculated from Medicare claims data. For the purpose of plotting the proportion who received erythropoietin, the first month of dialysis treatment was considered month 1 of follow-up. For the purpose of examining erythropoietin dose and associated hemoglobin level among patients who received erythropoietin, the first month of erythropoietin use was considered month 1 of follow-up. Follow-up was censored at transplantation, change in dialysis modality, or death.
The proportions of hemodialysis and peritoneal dialysis patients who received erythropoietin during the first year of dialysis therapy were compared using generalized estimating equations, adjusted for baseline characteristics. Average monthly erythropoietin doses and associated hemoglobin levels were compared using a generalized linear mixed model with repeated measurements and unstructured covariance, adjusted for baseline characteristics. All analyses were conducted using SAS version 8.2 (SAS Institute, Cary, NC). Figure 1 illustrates the inclusion criteria filtering effect. Twenty percent were excluded because they did not have Medicare as the primary payer, 22% because they had a switch in dialysis modality in the first 6 mo of dialysis therapy, and 0.004% because records showed a Medicare claim for erythropoietin before initiation of dialysis therapy. Patient characteristics at dialysis inception are shown in Table 1 . As compared with peritoneal dialysis patients, hemodialysis patients were (P Ͻ 0.05) more likely to be black, male, and unemployed or retired; more likely to have ESRD from diabetes or hypertension; less likely to be current smokers; and more likely to have cardiovascular disease, cancer, ambulation difficulties, low GFR, hypoalbuminemia, and severe anemia.
Results
The proportion of patients who received erythropoietin reached a plateau at 3 mo in both groups: approximately 25% in peritoneal dialysis patients and 80% in hemodialysis patients ( Figure 2 ). Average total monthly dose of erythropoietin reached a plateau of approximately 30,000 units in peritoneal dialysis patients and 60,000 units in hemodialysis patients (Figure 3, left) . The disparities between the hemodialysis and peritoneal dialysis groups in proportions using erythropoietin and in average monthly dose were unchanged after adjustment for the baseline characteristics shown in Table 1 .
Given that outpatient erythropoietin claims were the outcome studied, an imbalance in hospitalization rates could lead to a biased comparison. However, hemodialysis patients with at least one hospitalization in a given month had lower average total monthly dose, whereas the monthly doses for hospitalized versus nonhospitalized peritoneal dialysis patients were not substantially different (Figure 3, right) .
In both the hemodialysis and peritoneal dialysis groups, the DOQI hemoglobin target level was reached by the third month Figure 1 . Study population. Diagram shows how the inclusion criteria led to the final sample sizes for both the erythropoietin (EPO) utilization analysis and the EPO dose/hemoglobin analysis. PD, peritoneal dialysis; HD, hemodialysis. of erythropoietin therapy ( Figure 4 ). Subsequently, each group had similar mean hemoglobin levels. Before the fifth month, peritoneal dialysis patients had higher hemoglobin levels (P Ͻ 0.0001); hemoglobin levels thereafter were equivalent (P Ͼ 0.05).
Discussion
We found that, among older Medicare enrollees, patients who received peritoneal dialysis were substantially less likely to have initiated erythropoietin than patients who received hemodialysis. In both groups, the time from initiation of erythropoietin to the establishment of a DOQI-compliant hemoglobin level (11 to 12 g/dl) was approximately 3 mo. Hemoglobin levels achieved after initiation of erythropoietin were similar; however, erythropoietin doses were notably higher among hemodialysis patients. For any month in which the hemoglobin level had stabilized in the DOQI-recommended range, erythropoietin claims were submitted for approximately 25% of peritoneal dialysis patients and approximately 80% of hemodialysis patients. At steady state, the doses used in hemodialysis patients were approximately double those used in peritoneal dialysis patients. The finding that erythropoietin doses were higher in hemodialysis patients was expected. The dose disparity, however, was not.
There are surprisingly few direct comparisons of erythropoietin use in peritoneal dialysis and hemodialysis patients. It is unlikely that random assignment to hemodialysis or peritoneal dialysis will ever be used to study erythropoietin doses. It is likely that biologic factors underlie some of the disparities in erythropoietin dose seen in this study. In the United States, erythropoietin is usually given intravenously to hemodialysis patients and subcutaneously to peritoneal dialysis patients. The subcutaneous route is believed to be more efficacious in terms of hemoglobin level achieved (22, 23) . For example, in an investigation by the Veterans Affairs Cooperative Study Group, hemodialysis patients were randomly assigned to receive either subcutaneous or intravenous erythropoietin. At steady state, erythropoietin doses were 32% lower with use of the subcutaneous route (22) . Observational data suggest that anemia is less common and more sensitive to erythropoietin in peritoneal dialysis patients than in hemodialysis patients, possibly because blood loss is less marked and residual renal function may be better preserved in patients who receive peritoneal dialysis (12) (13) (14) (15) (16) (17) (18) (19) (20) . Also, in hemodialysis patients, blood is usually drawn before a dialysis session; as a result, hemoglobin is likely to be partly diluted. Compliance differences may explain some of our findings, but this issue could not be addressed in this investigation of Medicare claims.
Our study was restricted to older patients in the first year of dialysis therapy. It was not a prospective study with the a priori objective of comparing erythropoietin doses in hemodialysis and peritoneal dialysis patients. It is likely that hemodialysis patients, on average, have more comorbid conditions at the inception of dialysis therapy, which may well decrease erythropoietin responsiveness. In this study, hemodialysis patients were clearly more likely to have comorbid conditions at baseline and had lower estimated GFR and hemoglobin levels at dialysis inception. Residual renal function can clear larger solutes and produce erythropoietin. This may explain the higher circulating erythropoietin levels reported in pediatric peritoneal dialysis patients (24) . The disparities in erythropoietin dose were largely unaffected when adjustment was made for differences in measured comorbidity. It is possible that differences in unmeasured comorbidity could account for the dosing disparity, a contingency that is impossible to assess directly. However, it is notable that adjustment for hospitalization had only a marginal impact on erythropoietin dose, which suggests that comorbidity differences before and after dialysis inception cannot explain the observed disparities. In addition, the relative speed with which the DOQI hemoglobin target level was met and the stability of the hemoglobin levels and erythropoietin dosages thereafter tend to argue against the possibility that ongoing comorbidity differences is a sufficient explanation for the disparity in erythropoietin use.
This study has limitations. A Medicare claim for erythropoietin was a precondition for defining the evolution of erythropoietin-hemoglobin relationships; therefore, the hemoglobin levels of patients who did not receive erythropoietin could not be investigated. The findings of the Peritoneal Dialysis Clinical Performance Measures Project suggest that peritoneal dialysis patients who do not receive erythropoietin are not profoundly anemic. In that project, prevalence data from random national samples of adult peritoneal dialysis patients who participated in the United States End-Stage Renal Disease program have been collected annually since 1995. Between 1995 and 2000, the mean hemoglobin level rose from 10.7 to 11.6 g/dl. In 2000, only 11% of peritoneal dialysis patients had an average hemoglobin level Ͻ10 g/dl (25) . Absolute iron deficiency, functional iron deficiency, and infection are common reasons for a poor response to erythropoietic agents; our study could not address these issues. Peritoneal dialysis patients seem to require substantially less intravenous iron than hemodialysis patients. For example, the United States Renal Data System has reported that fewer than one fifth of peritoneal dialysis patients receive intravenous iron by month 6 of dialysis therapy, as opposed to four fifths of hemodialysis patients (26) . This study included only subjects aged 65 yr or older, which limits gen- Figure 2 . Proportions of HD and PD patients receiving EPO over time. The proportions in the HD and PD groups differed (P Ͻ 0.0001) with and without adjustment for the baseline characteristics shown in Table 1. eralizability. In addition, a population of older peritoneal dialysis patients is likely to be more highly selected than their hemodialysis counterparts. It is equally likely that comorbidity adjustment only partly negates these selection imbalances.
It is tempting to speculate that economic considerations may have contributed to our findings. The homogeneity of the hemoglobin levels achieved and the heterogeneity of the erythropoietin doses used to achieve them are remarkable. The former suggests that the DOQI hemoglobin target guidelines have been broadly accepted and implemented, which represents a considerable achievement. The latter, however, suggests that the methods to achieve these guidelines are still in the realm of art, rather than science. Table  1 .
